Moreover, the 36-month beta value for SGMO is 1.37. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SGMO is 180.11M and currently, short sellers hold a 6.04% of that float. On April 10, 2024, SGMO’s average trading volume was 2.37M shares.
SGMO) stock’s latest price update
The stock of Sangamo Therapeutics Inc (NASDAQ: SGMO) has decreased by -0.53 when compared to last closing price of 0.57. Despite this, the company has experienced a -3.27% fall in its stock price over the last five trading sessions. Business Wire reported 2024-03-12 that RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
SGMO’s Market Performance
Sangamo Therapeutics Inc (SGMO) has experienced a -3.27% fall in stock performance for the past week, with a -37.93% drop in the past month, and a 9.25% rise in the past quarter. The volatility ratio for the week is 9.65%, and the volatility levels for the past 30 days are at 13.17% for SGMO. The simple moving average for the last 20 days is -21.01% for SGMO stock, with a simple moving average of -26.34% for the last 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with RBC Capital Mkts repeating the rating for SGMO by listing it as a “Sector Perform.” The predicted price for SGMO in the upcoming period, according to RBC Capital Mkts is $2 based on the research report published on November 03, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $1.50, previously predicting the price at $5. The rating they have provided for SGMO stocks is “Underperform” according to the report published on April 28th, 2023.
Wedbush gave a rating of “Outperform” to SGMO, setting the target price at $16 in the report published on February 27th of the previous year.
SGMO Trading at -28.78% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.84% of loss for the given period.
Volatility was left at 13.17%, however, over the last 30 days, the volatility rate increased by 9.65%, as shares sank -36.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.80% upper at present.
During the last 5 trading sessions, SGMO fell by -3.27%, which changed the moving average for the period of 200-days by -52.34% in comparison to the 20-day moving average, which settled at $0.6960. In addition, Sangamo Therapeutics Inc saw 3.52% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SGMO starting from BIOGEN INC., who sale 6,000,000 shares at the price of $0.50 back on Sep 26 ’23. After this action, BIOGEN INC. now owns 17,652,466 shares of Sangamo Therapeutics Inc, valued at $3,000,000 using the latest closing price.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -0.89 for the present operating margin
- 0.89 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -1.46. The total capital return value is set at -1.34. Equity return is now at value -136.48, with -70.85 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -5.9. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -1.38.
Currently, EBITDA for the company is -92.1 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 0.61. The receivables turnover for the company is 132.9for trailing twelve months and the total asset turnover is 1.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
To wrap up, the performance of Sangamo Therapeutics Inc (SGMO) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
